Abstract:Abstract Antibodies targeting programmed cell death protein-1 (PD-1) or its ligand PD-L1 rescue T cells from exhausted status and revive immune response against cancer cells. Based on the immense success in clinical trials, ten α-PD-1 (nivolumab, pembrolizumab, cemiplimab, sintilimab, camrelizumab, toripalimab, tislelizumab, zimberelimab, prolgolimab, and dostarlimab) and three α-PD-L1 antibodies (atezolizumab, durvalumab, and avelumab) have been approved for various types of cancers. Nevertheless, the low response rate of α-PD-1/PD-L1 therapy remains to be resolved. For most cancer patients, PD-1/PD-L1 pathway is not the sole speed-limiting factor of antitumor immunity, and it is insufficient to motivate effective antitumor immune response by blocking PD-1/PD-L1 axis. It has been validated that some combination therapies, including α-PD-1/PD-L1 plus chemotherapy, radiotherapy, angiogenesis inhibitors, targeted therapy, other immune checkpoint inhibitors, agonists of the co-stimulatory molecule, stimulator of interferon genes agonists, fecal microbiota transplantation, epigenetic modulators, or metabolic modulators, have superior antitumor efficacies and higher response rates. Moreover, bifunctional or bispecific antibodies containing α-PD-1/PD-L1 moiety also elicited more potent antitumor activity. These combination strategies simultaneously boost multiple processes in cancer-immunity cycle, remove immunosuppressive brakes, and orchestrate an immunosupportive tumor microenvironment. In this review, we summarized the synergistic antitumor efficacies and mechanisms of α-PD-1/PD-L1 in combination with other therapies. Moreover, we focused on the advances of α-PD-1/PD-L1-based immunomodulatory strategies in clinical studies. Given the heterogeneity across patients and cancer types, individualized combination selection could improve the effects of α-PD-1/PD-L1-based immunomodulatory strategies and relieve treatment resistance.

Post-translational regulations of PD-L1 and PD-1: Mechanisms and opportunities for combined immunotherapy

Emerging therapeutic frontiers in cancer: insights into posttranslational modifications of PD-1/PD-L1 and regulatory pathways

Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics

Progress in PD-1/PD-L1 inhibitors combined with other approaches in the treatment of non-small cell lung cancer

Strategies targeting PD-L1 expression and associated opportunities for cancer combination therapy

Posttranslational regulatory mechanism of PD-L1 in cancers and associated opportunities for novel small-molecule therapeutics

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation

Regulation of post-translational modification of PD-L1 and associated opportunities for novel small-molecule therapeutics

[Regulation of PD-L1 posttranslational modification and its application progress in tumor immunotherapy]

The opportunities and challenges in immunotherapy: Insights from the regulation of PD-L1 in cancer cells.

Regulation of PD-L1 expression in the tumor microenvironment

Combination strategies with PD-1/PD-L1 blockade: current advances and future directions

Generation, secretion and degradation of cancer immunotherapy target PD-L1

PD-1 regulation in immune homeostasis and immunotherapy

Recent Findings in the Posttranslational Modifications of PD-L1

Regulation of PD-L1: Emerging Routes for Targeting Tumor Immune Evasion

PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations

Extracellular and nuclear PD-L1 in modulating cancer immunotherapy

Recent advance of peptide-based molecules and nonpeptidic small-molecules modulating PD-1/PD-L1 protein-protein interaction or targeting PD-L1 protein degradation

Anti-Tumor Potential of Post-Translational Modifications of PD-1

Advances of PD-1/PD-L1 inhibitors in tumor immunotherapy